Back to Journals » Journal of Experimental Pharmacology » Volume 2

Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male wistar albino rats

Authors Onwuka F, Patrick-I wuanyanwu K, Nnodu C, Erhabor O 

Published 3 March 2010 Volume 2010:2 Pages 55—58

DOI https://doi.org/10.2147/JEP.S8586

Review by Single anonymous peer review

Peer reviewer comments 2



FC Onwuka1, KC Patrick-I wuanyanwu1, CK Nnodu1, O Erhabor2

1Department of Biochemistry, 2Department of Haematology, College of Health Sciences, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria

Abstract: This study was carried out to investigate the effect of prolonged intake of calcium-channel blocker amlodipine, an antihypertensive drug on gonadal steroid hormone (testosterone) of male albino rats. Three different concentrations of amlodipine (0.01, 0.02 and 0.03 mg/kg body weight) was administered orally to three different groups (B, C, and D) of experimental male wistar albino rats (n = 8) for six weeks. Group A rats were fed normal diet without amlodipine (n = 8) served as the control. The administration of amlodipine significantly reduced testosterone level in the following order, group A (0.22 ± 0.01) > B (0.18 ± 0.01) > C (0.14 ± 0.01) > D (0.10 ± 0.01). The reduction in testosterone levels corresponded with an increase in the concentration of amlodipine administered to male wistar albino rats. The observation in this study reveals that long-term treatment of male Wistar rats with calcium-channel blocker and antihypertensive (amlodipine) produces a significant reduction in the level of testosterone a hormone associated with decreased ability of men to enjoy sex and to develop good quality erections. There is the need for a large scale study to investigate the potential effect of long-term antihypertensive therapy with amlodipine on sexual dysfunction in men.

Keywords: calcium-channel blocker, amlodipine, antireproductive, antihypertensive drugs, gonadal steroid, and low libido

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.